Public consultation on the draft *Professional practice profile for pharmacists undertaking complex compounding*

28 April 2014

Responses to consultation questions

Please provide your feedback as a Word document (or equivalent)[1] to pharmacyconsultation@ahpra.gov.au by close of business on Monday 30 June 2014.

Stakeholder Details

If you wish to include background information about your organisation please provide this as a separate word document (not PDF).

Organisation name
N/A
Contact information *(please include contact person's name and email address)*
Dr Jenny Giam BPharm(Hons) PhD [redacted]

Your responses to consultation questions on the draft *Professional practice profile for pharmacists undertaking complex compounding*

1. Does the draft practice profile clearly explain its purpose, and how it should be used in relation to complex compounding?
2. Is there any content that needs to be changed, added or deleted in the draft practice profile in relation to complex compounding?
Page 8, Item 17 **Definition of complex compounding** – the definition is similar to, but not identical to the definition in the current APF. There is potential contradiction in defining micro-dose single unit dosage forms containing less than 25mg of active ingredient as 'complex' but then including all single unit dosage forms (tablets, capsules, troches) as 'complex'. Is a moulded tablet or capsule containing more than 25mg a 'complex' compounded product? I assume the concern is dose uniformity associated with micro-dose products rather than all single unit dosage forms. The APF definition seems more appropriate.

[1] You are welcome to supply a PDF file of your feedback in addition to the word (or equivalent) file, however we request that you do supply a text or word file. As part of an effort to meet international website accessibility guidelines, AHPRA and National Boards are striving to publish documents in accessible formats (such as word), in addition to PDFs. More information about this is available at www.ahpra.gov.au/About-AHPRA/Accessibility.aspx.

Domain 5, Standard 5.4 Element 4 – This section on protecting personal health should be applied to all compounding of hazardous ingredients and not limited to cytotoxic products. For example there are hazards to personnel from exposure to hormones, irritants, sensitising agents and needle stick injury as well as from cytotoxics. **Domain 5, Standard 5.3, Element 1.4** – "Ability to describe the key features of a quality assurance program for aseptic preparation of compounded products" should also be applicable to non-sterile and cytotoxic compounding.
3. Do you have any suggestions for questions to be answered in Frequently Asked Questions developed by the Board, to assist pharmacists in using the practice profile for complex compounding?
4. Do you have any other comments on the draft practice profile?

Please provide your feedback as a Word document (or equivalent) to pharmacyconsultation@ahpra.gov.au by close of business on Monday 30 June 2014.